Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.

Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ.

Cancer Res. 2013 Mar 1;73(5):1547-58. doi: 10.1158/0008-5472.CAN-12-3343. Epub 2013 Feb 22.

2.

Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.

Quetglas JI, Dubrot J, Bezunartea J, Sanmamed MF, Hervas-Stubbs S, Smerdou C, Melero I.

Mol Ther. 2012 Sep;20(9):1664-75. doi: 10.1038/mt.2012.56. Epub 2012 Jun 26.

3.
4.

Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity.

Zhang Y, Li N, Suh H, Irvine DJ.

Nat Commun. 2018 Jan 2;9(1):6. doi: 10.1038/s41467-017-02251-3.

5.

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K.

Clin Immunol. 2007 Oct;125(1):76-87. Epub 2007 Aug 13.

PMID:
17706463
6.

The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.

Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Peñuelas I, Hervás-Stubbs S, Rouzaut A, de Landázuri MO, Jure-Kunkel M, Aragonés J, Melero I.

Cancer Discov. 2012 Jul;2(7):608-23. doi: 10.1158/2159-8290.CD-11-0314. Epub 2012 Jun 19.

7.

Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.

Jackaman C, Nelson DJ.

Cancer Immunol Immunother. 2012 Apr;61(4):549-60. doi: 10.1007/s00262-011-1120-5. Epub 2011 Oct 15.

PMID:
22002241
8.

Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.

Kuhn S, Hyde EJ, Yang J, Rich FJ, Harper JL, Kirman JR, Ronchese F.

J Immunol. 2013 Aug 15;191(4):1984-92. doi: 10.4049/jimmunol.1301135. Epub 2013 Jul 15.

9.

Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy.

Kwong B, Liu H, Irvine DJ.

Biomaterials. 2011 Aug;32(22):5134-47. doi: 10.1016/j.biomaterials.2011.03.067. Epub 2011 Apr 22.

10.

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.

Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

11.

IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ.

J Immunol. 2003 Nov 15;171(10):5051-63.

12.
13.

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.

Weigelin B, Bolaños E, Teijeira A, Martinez-Forero I, Labiano S, Azpilikueta A, Morales-Kastresana A, Quetglas JI, Wagena E, Sánchez-Paulete AR, Chen L, Friedl P, Melero I.

Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7551-6. doi: 10.1073/pnas.1506357112. Epub 2015 Jun 1.

14.

Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.

Dubrot J, Palazón A, Alfaro C, Azpilikueta A, Ochoa MC, Rouzaut A, Martinez-Forero I, Teijeira A, Berraondo P, Le Bon A, Hervás-Stubbs S, Melero I.

Int J Cancer. 2011 Jan 1;128(1):105-18. doi: 10.1002/ijc.25333.

15.

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.

Dubrot J, Milheiro F, Alfaro C, Palazón A, Martinez-Forero I, Perez-Gracia JL, Morales-Kastresana A, Romero-Trevejo JL, Ochoa MC, Hervás-Stubbs S, Prieto J, Jure-Kunkel M, Chen L, Melero I.

Cancer Immunol Immunother. 2010 Aug;59(8):1223-33. doi: 10.1007/s00262-010-0846-9. Epub 2010 Mar 25.

PMID:
20336294
16.
17.

Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.

Santos JM, Havunen R, Siurala M, Cervera-Carrascon V, Tähtinen S, Sorsa S, Anttila M, Karell P, Kanerva A, Hemminki A.

Int J Cancer. 2017 Oct 1;141(7):1458-1468. doi: 10.1002/ijc.30839. Epub 2017 Jun 29.

PMID:
28614908
18.

Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.

Contreras A, Sen S, Tatar AJ, Mahvi DA, Meyers JV, Srinand P, Suresh M, Cho CS.

Cancer Immunol Immunother. 2016 May;65(5):601-11. doi: 10.1007/s00262-016-1823-8. Epub 2016 Mar 24.

19.

Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.

Søndergaard H, Galsgaard ED, Bartholomaeussen M, Straten PT, Odum N, Skak K.

J Immunother. 2010 Apr;33(3):236-49. doi: 10.1097/CJI.0b013e3181c0c1cb.

PMID:
20445344
20.

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.

Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, Zhang S.

J Transl Med. 2013 Sep 17;11:215. doi: 10.1186/1479-5876-11-215.

Supplemental Content

Support Center